Logo
x

Search

Subscribe Now

Shanghai Henlius

The NMPA Clears Shanghai Henlius’ IND Application of HLX17 (Biosimilar, Keytuda) for Treating Solid Tumors

The NMPA Clears Shanghai Henlius’ IND Application of HLX17 (Biosimilar, Keytuda) for Treating Solid Tumors

  • September 2, 2024
Shanghai Henlius and Organon Got EMA’s Validation for the MAA of HLX14 (Biosimilar, Prolia & Xgeva)

Shanghai Henlius and Organon Got EMA’s Validation for the MAA of HLX14 (Biosimilar, Prolia & Xgeva)

  • May 24, 2024
Accord BioPharma’s Hercessi (Biosimilar, Herceptin) Receives the US FDA Approval

Accord BioPharma’s Hercessi (Biosimilar, Herceptin) Receives the US FDA Approval

  • April 29, 2024
Henlius and Organon Report the P-III Study Results of HLX14 (Biosimilar, Denosumab)

Henlius and Organon Report the P-III Study Results of HLX14 (Biosimilar, Denosumab)

  • April 8, 2024
Shanghai Henlius Reports P-III Placebo-Controlled Trial Results of HLX01 (biosimilar, rituximab) for Active Rheumatoid Arthritis

Shanghai Henlius Reports P-III Placebo-Controlled Trial Results of HLX01 (biosimilar, rituximab) for Active Rheumatoid Arthritis

  • October 10, 2022
Henlius and Organon Report the P-III Study Results of HLX14 (Biosimilar, Denosumab)

    Henlius and Organon Report the P-III Study Results of HLX14 (Biosimilar, Denosumab)

    • April 8, 2024
    Insights+ Key Biosimilars Events of February 2024

      Insights+ Key Biosimilars Events of February 2024

      • March 4, 2024
      Shanghai Henlius Biotech Reports the Results of HLX01 (biosimilar, rituximab) in P-III Trial for the Treatment of Diffuse Large B-Cell Lymphoma

        Shanghai Henlius Biotech Reports the Results of HLX01 (biosimilar, rituximab) in P-III Trial for the Treatment of Diffuse Large B-...

        • February 6, 2024
        Insights+ Key Biosimilars Events of June 2023

          Insights+ Key Biosimilars Events of June 2023

          • July 5, 2023
          Shanghai Henlius Biotech Receives the NMPA’s IND Approval of HLX13 (biosimilar, ipilimumab) for the Treatment of Hepatocellular Carcinoma

            Shanghai Henlius Biotech Receives the NMPA’s IND Approval of HLX13 (biosimilar, ipilimumab) for the Treatment of Hepatocellular Ca...

            • June 26, 2023
            PharmaShots

              PharmaShots' Key Highlights of First Quarter 2023

              • April 3, 2023
              Image

              Incisive News in 3 Shots.

              Contact Us

              Our Information

              Follow Us

              Copyright © 2025 PharmaShots - All Rights Reserved.